Deciphera Pharmaceuticals, Inc. provided a corporate update and highlighted key 2020 milestones in conjunction with its presentation at the 38th Annual J.P. Morgan Healthcare Conference in San Francisco. The Company announced that two additional marketing applications have been submitted for ripretinib as part of the U.S. Food and Drug Administration’s (FDA) Project Orbis pilot program. The marketing applications of ripretinib for advanced GIST in Canada and Australia have both received priority review designations. The Project Orbis pilot program, an initiative of the FDA Oncology Center of Excellence, is designed to provide a framework for concurrent submission and review of oncology products among international partners. In 2020, the Company seeks to achieve the following milestones: Ripretinib: Potential FDA approval and commercial launch of ripretinib in advanced GIST; Submit marketing authorization application to European Medicines Agency; Complete enrollment of INTRIGUE Phase 3 study in 2nd line GIST; Present Phase 1 study expansion data; DCC- 3014: Select Phase 2 dose for tenosynovial giant cell tumor (TGCT) patients and open expansion cohort; Provide update on Phase 1 data in TGCT patients; Rebastinib: Selected Phase 2 dose of 100 mg BID of rebastinib and activated Part 2 of Phase 1b/2 study in combination with carboplatin. (Completed January 2020); Present Phase 1b/2 data in combination with carboplatin; Present Phase 1b/2 data in combination with paclitaxel; and DCC-3116: Submit an Investigational New Drug (IND) application to FDA.